Stoke Therapeutics (STOK) Equity Average (2018 - 2026)

Stoke Therapeutics' Equity Average history runs 9 years deep, the most recent figure standing at $373.7 million for Q1 2026.

• In Q1 2026, Equity Average rose 29.05% year-over-year to $373.7 million; the TTM figure through Mar 2026 stood at $373.7 million (up 29.05% YoY), while the FY2025 annual figure was $290.7 million, up 49.64% from the prior year.
• Equity Average was $373.7 million for Q1 2026 at Stoke Therapeutics, up from $330.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $373.7 million in Q1 2026 to a low of $150.0 million in Q1 2024.
• Historically, Equity Average has averaged $240.4 million across 5 years, with a median of $228.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Equity Average decreased 24.77% in 2024, then soared 93.09% in 2025.
• A 5-year view of Equity Average shows it stood at $194.5 million in 2022, then decreased by 14.51% to $166.3 million in 2023, then soared by 38.66% to $230.6 million in 2024, then surged by 43.25% to $330.3 million in 2025, then grew by 13.14% to $373.7 million in 2026.
• The last three Equity Average figures came in at $373.7 million (Q1 2026), $330.3 million (Q4 2025), and $321.5 million (Q3 2025), per Business Quant data.